FDC Ltd

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This transition, driven by changes in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a detailed analysis of its price attractiveness relative to historical levels and peer companies within the sector.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in technical indicators and a return to positive financial performance. The MarketsMOJO Mojo Score now stands at 58.0, signalling cautious optimism amid mixed long-term fundamentals and valuation concerns.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently exhibited a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a slight dip in the latest session, the stock’s technical indicators reveal a complex interplay of bullish and bearish signals, suggesting cautious optimism for investors analysing its near-term prospects.

The 50-day moving average has crossed above the 200-day moving average for FDC Ltd, signalling a golden cross on 16 Jul 2026. Yet, the stock declined 0.59% on the day the cross formed, while monthly momentum indicators remain bearish. This juxtaposition of signals calls for a detailed examination of whether the golden cross is a reliable indicator or a misleading signal in this context.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest day gain of 0.68% to close at ₹424.40, the stock’s technical indicators present a complex picture, with bullish signals on weekly charts contrasting bearish monthly trends. This nuanced technical landscape, combined with a recent downgrade in its Mojo Grade from Hold to Sell, warrants a detailed analysis for investors seeking clarity on the stock’s near-term trajectory.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent downgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical indicators reveal a nuanced picture that investors should carefully analyse.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 8 July 2026. This shift reflects a combination of deteriorating technical indicators, valuation concerns, and subdued long-term financial growth despite recent quarterly improvements. The company’s current Mojo Score stands at 48.0, reinforcing the cautious stance among investors.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, which collectively suggest a nuanced outlook for investors navigating the stock’s near-term trajectory.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 3 July 2026. This change reflects a combination of improved technical indicators, a rebound in financial performance, and a more balanced valuation outlook, signalling cautious optimism among investors.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend. Despite a slight dip in the day’s price, the stock’s technical indicators present a nuanced picture, with weekly signals generally positive while monthly trends remain cautious. This article analyses the recent technical parameter changes, key momentum indicators, and the stock’s relative performance against the Sensex to provide a comprehensive outlook for investors.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite a modest day gain of 0.86% to close at ₹434.10, the stock’s technical indicators present a complex picture, with weekly signals largely bullish contrasting with bearish monthly trends, prompting a cautious outlook from analysts.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, which collectively paint a nuanced picture of the stock’s near-term prospects.

FDC Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 June 2026, providing investors with the most up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably, with its price-to-earnings (P/E) and price-to-book value (P/BV) ratios moving from fair to expensive territory. This change, coupled with a recent upgrade in its Mojo Grade from Strong Sell to Sell, invites a closer examination of its price attractiveness relative to historical levels and peer benchmarks.

FDC Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. Despite a recent 5.04% decline in its share price to ₹380.75 on 8 June 2026, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest improved price attractiveness relative to its historical and peer averages. This article analyses the valuation changes, compares FDC’s metrics with sector peers, and assesses the implications for investors amid a challenging market backdrop.

FDC Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 June 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.